Top Markets
Coin of the day
GH Research PLC GH Research PLC

GH Research PLC

GHRS
Classifica tra le azioni #6594
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to... GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Prezzo delle azioni
$28.53
Capitalizzazione di mercato
$1.96B
Variazione (1 giorno)
-1.65%
Variazione (1 anno)
109.32%
Paese
IE
Scambia GH Research PLC (GHRS)

Categoria

Cronologia dei frazionamenti azionari per GH Research PLC (GHRS)
L’azione GH Research PLC (simbolo: GHRS) ha subito un totale di 0 frazionamenti.
L’ultimo frazionamento è avvenuto il Aug 28, 2026.
Una quota di GHRS acquistata prima di Aug 28, 2026 equivale oggi a 0 quote di GHRS.
Elenco dei frazionamenti azionari
Anno Frazionamento Moltiplicatore Moltiplicatore cumulativo
Non abbastanza dati per le date fornite.
Frazionamenti azionari di aziende simili o concorrenti
Azienda Numero di frazionamenti azionari Moltiplicatore cumulativo Il paese
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH